Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delafloxacin versus best available treatment for surgical site infections
2018-001082-17Phase 3Terminated
- Sponsor
- Menarini Group
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of delafloxacin in surgical site infection (SSI), acute bacterial skin and skin structure infection (ABSSSI), bacterial infections of skin and subcutaneous tissue (SSTI), sponsored by Menarini Group. Started Jun 2019; status: terminated.
02
Drugs
delafloxacin
03
Conditions
surgical site infection (SSI)acute bacterial skin and skin structure infection (ABSSSI)bacterial infections of skin and subcutaneous tissue (SSTI)
Beyond the preview
Go deeper on 2018-001082-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001082-17.